José M. Buesa

José M. Buesa

Auto-generated profile, based on publicly available information

José M. Buesa

Hospital Central de Asturias

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Sarcoma
Verified
Journal Article
Open access
PDF file
APA. Poveda
A. Poveda
ALAntonio López-Pousa
Antonio López-Pousa
Javier Martin-BrotoJavier Martin-Broto
Javier Martin-Broto
JMJ. García Del Muro
J. García Del Muro
RBR. Bernabé
R. Bernabé
JBJ. M. Buesa
J. M. Buesa
Background: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR.Patients and methods: Patients with measurable and progressive STS received PLD at 35 mg/m2 every 3 weeks. Quality of life before and during treatment was assessed with EORTC QLQ‐C30.Results: Twenty‐eight patients, 22 DXR‐pretreated, were given 140 cycles (median 3, range 1–18). Activity in 27 patients (5 GIST): one complete and one partial remission (both non‐GIST and without prior DXR), 12 stabilizations and 13 progressions (response rate 7.4%, 95% CI: 0–17%). Grade 3 toxicity: palmar‐plantar erythrodysesthesia (19% of patients), stomatitis (4%) or cutaneous (4%). Neutropenia grade≥3 was detected in 16% of patients. Median relative dose intensity was 95%. Progression‐free rate at 3 and 6 months was, respectively, 48 and 22%, median progression‐free survival 5.8 months and median overall survival 8.7 months. QLQ‐C30 at baseline and at weeks 6–11 in 23 and 13 patients, respectively, showed good reliability and validity. Quality of life did not seem to worsen during therapy.Conclusions: PLD did not induce objective remissions in 22 STS patients pretreated with DXR, but progression‐free rate figures support the use of this agent in patients who have not progressed under a DXR‐containing regimen. The toxicity observed was comparable to that of other PLD schedules.

31 May 2006 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
RLR. Losa
R. Losa
JRJoaquín Fra Rodríguez
Joaquín Fra Rodríguez
ALAntonio López-Pousa
Antonio López-Pousa
MSM. Sierra
M. Sierra
AGA. Goitia
A. Goitia
JBJosé M. Buesa
José M. Buesa

13 October 2004 in Cancer
Verified
Journal Article
Open access
PDF file
JBJosé M. Buesa
José M. Buesa
RLRaquel Losa
Raquel Losa
AFAida Fernández
Aida Fernández
MSMarta Sierra
Marta Sierra
EEEmilio Esteban
Emilio Esteban
JRJoaquín Fra Rodríguez
Joaquín Fra Rodríguez
BACKGROUND In the current study, the authors set out to determine the dose‐limiting toxicity (DLT) and maximum tolerated dose (MTD) associated with a combination of gemcitabine and dacarbazine (DTIC) in patients with advanced soft tissue sarcoma (ASTS), to obtain preliminary information on the activity of this combination, and to explore possible pharmacodynamic interactions between gemcitabine and DTIC. METHODS Every 2 weeks, 22 patients with refractory ASTS received fixed–dose rate gemcitabine (10 mg/m2/min) at escalating doses, which ranged from 800 mg/m2 to 2160 mg/m2, plus 500 mg/m2 DTIC. Plasma concentrations of gemcitabine and 2′,2′‐difluorodeoxyuridine, along with gemcitabine triphosphate (dFdCTP) levels in peripheral blood mononuclear cells (PBMCs), were evaluated during the course of treatment. RESULTS Grade 3 elevation of transaminase and γ‐glutamyltransferase levels represented the DLT associated with the administration of 2160 mg/m2 gemcitabine plus 500 mg/m2 DTIC. This side effect was reversible, rather than cumulative, and did not exceed Grade 3 in its severity. The doses recommended for use in subsequent Phase II studies are 1800 mg/m2 gemcitabine (administered over the course of 3 hours) and 500 mg/m2 DTIC. Hematologic toxicity was moderate, and nonhematologic side effects that did not exceed Grade 2 in severity included the following: asthenia (75% of patients), fever (59%), nausea (52%), stomatitis (48%), anorexia (44%), emesis (40%), flulike syndrome (37%), and erythematous rash (26%). Alopecia was common. Intracellular dFdCTP levels, which were evaluated in 6 patients, reached a mean maximum value of 209 pmol per 106 cells (standard deviation, 59 pmol per 106 cells) at the conclusion of gemcitabine administration. DTIC had a limited effect on the elimination of dFdCTP from PBMCs. Objective responses were observed in 5 of the 19 patients who were evaluable for treatment efficacy. CONCLUSIONS The combination of gemcitabine and DTIC possesses an acceptable toxicity profile and may warrant further investigation in patients with ASTS. Cancer 2004. © 2004 American Cancer Society.

1 January 2006 in Sarcoma
Verified
Journal Article
Open access
PDF file
ALAntonio López-Pousa
Antonio López-Pousa
Javier Martin-BrotoJavier Martin-Broto
Javier Martin-Broto
JMJ. Montalar
J. Montalar
RPR. de Las Peñas
R. de Las Peñas
JMJ. García del Muro
J. García del Muro
T(the Spanish Group for Research on Sarcomas (GEIS)
the Spanish Group for Research on Sarcomas (GEIS)
Background. To explore the tolerance and the activity of high‐dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m2 every 4 weeks in patients with soft tissue sarcomas. Methods. DXR was given IV bolus and IFOS by continuous infusion at 2 g/m2/day. Initial IFOS dose (12 g/m2) was adjusted to 10, 13, or 14 g/m2 according to toxicity. Results. Seventy patients received 277 cycles (median 3 cycles, range 1–10), 34% with IFOS dose increased, 30% decreased, and 48% delivered at 12 g/m2. Toxicity grade 4 occurred on granulocytes (67% of patients) or platelets (19%), 54% had febrile neutropenia, 31% grade 3/4 asthenia, and 26% abandoned the study due to toxicity. Three toxic deaths occurred. In 57 non‐GIST patients objective activity was 45.6% (95% CI, 32 to 58%). Conclusion. At least 4 cycles were tolerated by 71% of patients, most receiving DXR 50 mg/m2 plus IFOS 10–12 g/m2, with substantial toxicity.

23 May 2006 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ALAntonio López-Pousa
Antonio López-Pousa
RLR Losa
R Losa
Javier Martin-BrotoJavier Martin-Broto
Javier Martin-Broto
JMJ Maurel
J Maurel
JFJ Fra
J Fra
JBJ M Buesa
J M Buesa
The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of doxorubicin and gemcitabine in adult patients with advanced soft tissue sarcomas and to explore its activity and toxicity, and the presence of possible interactions between these agents. Patients with measurable disease were initially treated with doxorubicin 60 mg m−2 by i.v. bolus on day 1 followed by gemcitabine at 800 mg m−2 over 80 min on days 1 and 8, every 21 days. Concentrations of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma, and gemcitabine triphosphate levels in peripheral blood mononuclear cells were determined during 8 h after the start of gemcitabine infusion. Myelosuppression and stomatitis were limiting toxicities, and the initial dose level was applied for the Phase II trial, where grade 3–4 granulocytopenia occurred in 70% of patients, grade 3 stomatitis in 46% and febrile neutropenia in 20%. Objective activity in 36 patients was 22% (95% CI: 9–35%), and a 50% remission rate was noted in leiomyosarcomas. Administration of doxorubicin preceding gemcitabine significantly reduced the synthesis of gemcitabine triphosphate. Clinical activity, similar to that of single-agent doxorubicin, and the toxicity encountered do not justify further studies with this schedule of administration.